Motion for pharmaceutical pricing transparency passed

Speaking in favour of the motion, Dublin GP Dr Ray Walley said that “new pharmaceutical products have often been subsidised by public funds. The IMO should support the efforts for improved transparency on behalf of pharmaceutical companies in an effort to ensure fairer return on public investment… we need transparency in all of this.”